Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Randomized Clinical Trial
100%
High Cardiovascular Risk
100%
Placebo
100%
Renal Risk
100%
Major Adverse Cardiovascular Events
100%
Linagliptin
100%
Usual Care
42%
Hazard Ratio
28%
Once-daily
28%
Cardiovascular Risk
28%
End-stage Renal Disease
28%
Cardiovascular Outcomes
28%
Albumin-to-creatinine Ratio
28%
Dipeptidyl peptidase-4 (DPP-4)
28%
First Occurrence
28%
Number of Patients
14%
Randomized Placebo-controlled Trial
14%
High Risk
14%
Type 2 Diabetic Patients
14%
Placebo Groups
14%
Insulin
14%
Incidence Rate
14%
Non-inferiority Trial
14%
Vascular Disease
14%
Chronic Kidney Disease
14%
Clinical Practice Guidelines
14%
Microalbuminuria
14%
Cardiovascular Mortality
14%
Infarction
14%
Renal Failure
14%
Non-inferiority
14%
Hemoglobin A1c (HbA1c)
14%
Glucose-lowering Drugs
14%
Nonfatal Stroke
14%
Cardiovascular Safety
14%
Kidney Outcomes
14%
Rate Difference
14%
Kidney Events
14%
Reduced eGFR
14%
Medicine and Dentistry
Cardiovascular System
100%
Maturity Onset Diabetes of the Young
100%
Placebo
100%
Randomized Clinical Trial
100%
Linagliptin
100%
Cardiovascular Risk
37%
Creatinine
25%
End Stage Renal Disease
25%
Drug Therapy
25%
Hazard Ratio
25%
Dipeptidyl Peptidase-4 Inhibitor
25%
Chronic Kidney Disease
12%
Apoplexy
12%
Infarction
12%
Patient with Type 2 Diabetes
12%
Vascular Disease
12%
Renal Failure
12%
Clinical Guideline
12%
Noninferiority Trial
12%
Macroalbuminuria
12%
Hemoglobin A
12%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Placebo
100%
Randomized Clinical Trial
100%
Linagliptin
100%
Cardiovascular Risk
42%
Creatinine
28%
End Stage Renal Disease
28%
Dipeptidyl Peptidase IV Inhibitor
28%
Chronic Kidney Failure
14%
Infarction
14%
Vascular Disease
14%
Kidney Failure
14%
Noninferiority Trial
14%
Macroalbuminuria
14%
Hemoglobin A
14%